Neoadjuvant Therapy of PD-1 Blockade Combined With Chemotherapy for Esophageal Carcinoma

Last updated: March 8, 2023
Sponsor: Beijing Friendship Hospital
Overall Status: Active - Recruiting

Phase

1/2

Condition

Esophageal Cancer

Carcinoma

Esophageal Disorders

Treatment

N/A

Clinical Study ID

NCT05777707
BeijingHF
  • Ages 18-89
  • All Genders

Study Summary

This prospective study aims to clarify the clinical efficacy and survival prognosis of neoadjuvant immune checkpoint inhibitor (ICI) combined with chemotherapy for esophageal cancer. It also explores predictive biomarkers and potential therapeutic targets for locally advanced esophageal cancer based on plasma metabolomics and peripheral blood immune cell clustering analysis. Each patient received 2-3 cycles of neoadjuvant immunotherapy with programmed cell death 1 (PD-1) blockade in combination with albumin paclitaxel and platinum. Exploratory analysis of plasma metabolomics combined with peripheral blood subsets of immune cells can reveal biomarkers that predict the efficacy and prognosis of patients undergoing neoadjuvant immunotherapy for locally advanced esophageal cancer, which also provide new ideas for the selection of immune adjuvants and therapeutic targets in ICIs combination therapy strategies.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. age ≥ 18 years and ≤89 years;
  2. pathological histological examination confirmed the diagnosis of esophageal squamouscell carcinoma and esophageal adenocarcinoma;
  3. clinical stage II-IVA;
  4. adequate organ function;
  5. no previous chemotherapy or radiotherapy;
  6. voluntarily signed informed consent.

Exclusion

Exclusion Criteria:

  1. the presence of concurrent malignancies that interfere with the prognosis ofesophageal cancer;
  2. patients with immunodeficiency or autoimmune diseases that seriously affect the body'simmune system, such as those who test positive for HIV;
  3. patients undergoing systemic corticosteroid or other immunosuppressive treatments;
  4. patients with a history of allergy to the components of this test drug.

Study Design

Total Participants: 89
Study Start date:
October 29, 2020
Estimated Completion Date:
December 31, 2024

Connect with a study center

  • Qin li

    Beijing, Beijing 100029
    China

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.